Kegel8 Glossary - Medical terms without the jargon
123 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Tolterodine

What is Tolterodine?

Also known as Detrol, tolterodine is an anticholinergic medicine. It works to block nerves that control bladder muscle contractions and allow for relaxation of the smooth muscle of the bladder. These actions work together to help control urge urinary incontinence.

Tolterodine is used to treat Urge incontinence (UI) and overactive bladder (OAB).

Other incontinence medications available on prescription include:

Kegel8 Ultra 20 Electronic Pelvic Toner

477 Review(s)
£149.99

Darifenacin
Solifenacin
Trospium
Propiverine
Propiverine -extended release
Darifenacin -extended release
Fesoterodine -modified release
Oxybutynin - modified release
Oxybutynin - transdermal
Oxybutynin - topical gel
Trospium - extended release
Tolterodine - extended release

Electrical Stimulation vs Tolterodine for urge and urge incontinence*

Although anticholinergics are a mainstay of treatments for UI and OAB they are not without their problems and side effects. A prospective, randomised open trial was performed on 72 women in total. The 37 women on the electrical stimulation test had 10 treatments over 6 - 7 weeks, each treatment was 20 minutes. The patients on the drug trial received 4mg Tolterodine SR orally once daily.

There was a 73% improvement in the electrical stimulation group, and a 71% improvement in the tolterodine group, however 30% of the tolterodine group reported side effects. Researchers concluded that electrical stimulation could be considered in those patients who respond to tolterodine, but are unable or unwilling to continue with the drug due to its side effects.

Great news for Kegel8 Electronic Pelvic Toner users - and of course, do remember that no drug will strengthen your the pelvic floor muscles - so not only are you helping to combat UI and OAB - but also protecting your pelvic floor against prolapse too.

Drug free!

As always, Kegel8 is here to help you, call our helpline for more information.

Read More:

 

Franzen K Johansson, J E Lauridsen I, et al.

International Urogynecology Journal 2010;21:1517-24.